Regulatory News
Monday, July 25, 2016
Celgene drug fails to extend survival in lymphoma study
July 25 (Reuters) - Celgene Corp said on Monday
that its flagship drug Revlimid failed to extend survival as a
maintenance therapy for a type of blood cancer after patients
had responded to prior...
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment